Organisations representing genetics experts, pediatricians and patients are calling on health minister Edith Schippers not to act hastily on the health insurance council’s advice that expensive medicine payments should be scrapped.
They were reacting to advice given by the council on Sunday that payments for medicines used in the treatment of two metabolic disorders should be removed from the health insurance package.
The CVZ said that although the treatment does have an affect, their cost is too high in comparison with the results they deliver.
The medicine in question is used by patients suffering from the rare Pompe disease and Fabry disease. Annual treatment for one patient costs between €200,000 and €700,000.
The organisations have reminded the minister that she recently said she was happy with the way payments for expensive medicines is dealt with. ‘The patient with a rare disease has the right to equal treatment as a patient with a more common ailment,’ she wrote at the time.
According to press reports, it is highly likely Schippers will talk to the manufacturers about the cost of their medicines. At the moment, there is a big price difference for treatment for Pompe and Fabry in various countries.
The reports did not say if the Netherlands pays more than other countries.
Thank you for donating to DutchNews.nl
The DutchNews.nl team would like to thank all the generous readers who have made a donation in recent weeks. Your financial support has helped us to expand our coverage of the coronavirus crisis into the evenings and weekends and make sure you are kept up to date with the latest developments.
DutchNews.nl has been free for 14 years, but without the financial backing of our readers, we would not be able to provide you with fair and accurate news and features about all things Dutch. Your contributions make this possible.